Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2004-10-25
pubmed:abstractText
The angiogenic mediator vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) have been studied extensively in neoplastic disease and some inflammatory conditions. Contact hypersensitivity (CHS) is a prototypic Langerhans' cell-dependent, T-helper (Th) 1 cell-mediated inflammatory skin disease that is now also thought to involve angiogenic mediators. The purpose of our study was to examine the role of angiogenesis and VEGF in CHS. We demonstrated that VEGF production is up-regulated in murine skin after challenge with dinitrofluorobenzene. Administration of a monoclonal antibody directed against the VEGFR-2 (DC101) resulted in a 28.8% decrease in CHS response (P < 0.001). Examination of the DC101-treated mouse skin 24 h after challenge revealed decreases in dermal inflammatory cellular infiltrates and total vessel area. Furthermore, mRNA and protein of the Th1-type cytokine interferon (IFN)-gamma was significantly down-regulated in skin of DC101-treated animals 24 h after challenge. The results of the study demonstrate that VEGFR-2 blockade significantly reduces vascular enlargement and edema formation and effects IFN-gamma expression in the skin during challenge in CHS. Our findings suggest that DC101 could function by reducing inflammatory cell migration and hence IFN-gamma expression during the CHS response.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0906-6705
pubmed:author
pubmed:issnType
Print
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
671-81
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:15500639-Actins, pubmed-meshheading:15500639-Animals, pubmed-meshheading:15500639-Antibodies, Monoclonal, pubmed-meshheading:15500639-Dermatitis, Contact, pubmed-meshheading:15500639-Dinitrofluorobenzene, pubmed-meshheading:15500639-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:15500639-Female, pubmed-meshheading:15500639-Fluorescein-5-isothiocyanate, pubmed-meshheading:15500639-Immunohistochemistry, pubmed-meshheading:15500639-Inflammation, pubmed-meshheading:15500639-Interferon-gamma, pubmed-meshheading:15500639-Lectins, pubmed-meshheading:15500639-Mice, pubmed-meshheading:15500639-Mice, Inbred BALB C, pubmed-meshheading:15500639-Microscopy, Confocal, pubmed-meshheading:15500639-Neovascularization, Pathologic, pubmed-meshheading:15500639-RNA, Messenger, pubmed-meshheading:15500639-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:15500639-Skin, pubmed-meshheading:15500639-Th1 Cells, pubmed-meshheading:15500639-Time Factors, pubmed-meshheading:15500639-Up-Regulation, pubmed-meshheading:15500639-Vascular Endothelial Growth Factor A, pubmed-meshheading:15500639-Vascular Endothelial Growth Factor Receptor-2
pubmed:year
2004
pubmed:articleTitle
Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity.
pubmed:affiliation
Department of Dermatology, Johns Hopkins University, Baltimore, MD 21287-0900, USA.
pubmed:publicationType
Journal Article